WFA
IGMS

Wipfli Financial Advisors’s IGM Biosciences IGMS Stock Holding History

Wipfli Financial Advisors’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$2K Buy
+108
New +$2.18K ﹤0.01% 2291

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wipfli Financial Advisors's IGMS Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in IGM Biosciences (IGMS) in Q3 2022: 108 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #2291 among its holdings.

92 funds tracked by Wall St. Rank hold IGMS as of Q3 2022.

  • Wipfli Financial Advisors held 108 shares of IGM Biosciences worth $2K as of Q3 2022.
  • IGM Biosciences was a new Wipfli Financial Advisors position in Q3 2022.
  • IGM Biosciences made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2291 holding.
  • 92 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.